## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In re Patent Application of:

Von Der Kammer et al. Art Unit: 1633

Application No: 10/573,989 Examiner: K. T. Hiriyanna

Confirmation No: 9161

Filed: March 30, 2006 Atty. Docket No: 37998-237373

Customer No:

For: DIAGNOSTIC AND THERAPEUTIC USE OF A SULFOTRANSFERASE FOR NEURODEGENERATIVE DISEASES

26694 PATENT TRADEMARK OFFICE

## STATEMENT TO SUPPORT FILING AND SUBMISSION OF SEQUENCE LISTING

MS Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
- 2. the content of the attached paper copy of the Sequence Listing and CRF copy, submitted in accordance with 37.C.F.R. § 1.821(c) and (e), respectively, are the same;
- all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made

Application No.: 10/573,989 Docket No.: 37998-237373

with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Date: October 27,2008

Matthew E. Kelley Registration No. 55,887

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998 Telephone: (202) 344-4000 Telefax: (202) 344-8300

#991122v1